| Study ID | Study follow‐up (months) | CoronaVac/boost BNT162b2 (n) | CoronaVac/boost (n) | Critical outcomes | |||||||
| Confirmed SARS‐CoV‐2 infection after complete vaccination | Confirmed symptomatic COVID‐19 after complete vaccination | Severe or critical COVID‐19 | All‐cause mortality | Systemic reactogenicity events | Any AE | SAE | |||||
| Mok 2021 (NCT04611243) | 5.8 | 40 | 40 | * | * | * | * | ✓ | * | * | |
| Important outcomes | |||||||||||
| GMT of specific antibody against SARS‐COV‐2 | GMT of neutralizing antibody against SARSCOV‐2 | Local reactogenicity events | |||||||||
| * | * | ✓ | |||||||||
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.